4-MMPB

4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer[1][2][3][4].

Product Specifications

CAS Number

[928853-86-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; Lipoxygenase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/4-mmpb.html

Purity

98.54

Solubility

DMSO : 7.69 mg/mL (ultrasonic)

Smiles

CC1=C2NC3=C(SC2=NC(N4CCN(CC4)C)=N1)C=CC=C3

Molecular Formula

C16H19N5S

Molecular Weight

313.42

Precautions

H302, H315, H319

References & Citations

[1]Mohsen Nikpour, et al. Synthesis of new series of pyrimido[4,5-b][1,4] benzothiazines as 15-lipoxygenase inhibitors and study of their inhibitory mechanism. 2013, 22 (10), 5036-5043.|[2]Seyed Jamal Alavi, et al. A novel class of human 15-LOX-1 inhibitors based on 3-hydroxycoumarin. Chem Biol Drug Des. 2018 Jun;91 (6) :1125-1132.|[3]M Bakavoli, et al. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem. 2007 Mar 1;15 (5) :2120-6.|[4]Saffiyeh Saboormaleki, et al. 7-Farnesyloxycoumarin Exerts Anti-cancer Effects on a Prostate Cancer Cell Line by 15-LOX-1 Inhibition. Arch Iran Med. 2018 Jun 1;21 (6) :251-259.